Myomo Q3 EPS Estimate Lifted by Ascendiant Capital Markets

Myomo, Inc. (NYSEAMERICAN:MYO) – Research analysts at Ascendiant Capital Markets upped their Q3 2026 earnings per share estimates for shares of Myomo in a research note issued on Wednesday, August 26th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.09). Ascendiant Capital Markets currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.33) per share. Ascendiant Capital Markets also issued estimates for Myomo’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.32) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.22) EPS.

Myomo Price Performance

MYO stock opened at $1.49 on Tuesday. The company’s 50-day moving average price is $1.24 and its two-hundred day moving average price is $1.01. The firm has a market cap of $59.02 million, a P/E ratio of -4.38 and a beta of 1.50. The company has a quick ratio of 2.01, a current ratio of 2.31 and a debt-to-equity ratio of 1.98. Myomo has a 12 month low of $0.60 and a 12 month high of $1.89.

Myomo (NYSEAMERICAN:MYO) last posted its earnings results on Wednesday, August 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $11.70 million for the quarter, compared to the consensus estimate of $10.35 million. Myomo had a negative return on equity of 138.85% and a negative net margin of 33.53%.

Insider Activity at Myomo

In other Myomo news, Director Thomas F. Kirk purchased 40,002 shares of the stock in a transaction dated Friday, June 5th. The stock was bought at an average price of $1.27 per share, with a total value of $50,802.54. Following the acquisition, the director owned 693,865 shares of the company’s stock, valued at approximately $881,208.55. This represents a 6.12% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Harry Kovelman sold 17,250 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $1.73, for a total value of $29,842.50. Following the sale, the insider owned 105,983 shares of the company’s stock, valued at approximately $183,350.59. This represents a 14.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 12.14% of the company’s stock.

Institutional Trading of Myomo

A number of hedge funds have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. acquired a new position in shares of Myomo during the fourth quarter worth $641,000. Prescott Group Capital Management L.L.C. acquired a new stake in shares of Myomo during the 4th quarter valued at $169,000. XTX Topco Ltd acquired a new stake in shares of Myomo during the 2nd quarter valued at $134,000. Acadian Asset Management LLC bought a new stake in Myomo during the 1st quarter worth $114,000. Finally, Lazard Asset Management LLC acquired a new position in Myomo in the 2nd quarter worth about $98,000. Institutional investors and hedge funds own 44.99% of the company’s stock.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.